首页> 外文期刊>Chemical science >Unveiling the molecular mechanism of SARS-CoV-2 main protease inhibition from 137 crystal structures using algebraic topology and deep learning
【24h】

Unveiling the molecular mechanism of SARS-CoV-2 main protease inhibition from 137 crystal structures using algebraic topology and deep learning

机译:使用代数拓扑和深度学习揭示SARS-COV-2主要蛋白酶抑制的分子机制

获取原文
           

摘要

Currently, there is neither effective antiviral drugs nor vaccine for coronavirus disease 2019 (COVID-19) caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Due to its high conservativeness and low similarity with human genes, SARS-CoV-2 main protease (M ~(pro) ) is one of the most favorable drug targets. However, the current understanding of the molecular mechanism of M ~(pro) inhibition is limited by the lack of reliable binding affinity ranking and prediction of existing structures of M ~(pro) –inhibitor complexes. This work integrates mathematics ( i.e. , algebraic topology) and deep learning (MathDL) to provide a reliable ranking of the binding affinities of 137 SARS-CoV-2 M ~(pro) inhibitor structures. We reveal that Gly143 residue in M ~(pro) is the most attractive site to form hydrogen bonds, followed by Glu166, Cys145, and His163. We also identify 71 targeted covalent bonding inhibitors. MathDL was validated on the PDBbind v2016 core set benchmark and a carefully curated SARS-CoV-2 inhibitor dataset to ensure the reliability of the present binding affinity prediction. The present binding affinity ranking, interaction analysis, and fragment decomposition offer a foundation for future drug discovery efforts.
机译:目前,由急性呼吸综合征冠状病毒2(SARS-COV-2)引起的冠状病毒疾病(Covid-19)既没有有效的抗病毒药物也没有疫苗。由于其与人类基因的高保守性和低相似性,SARS-COV-2主要蛋白酶(M〜(Pro))是最有利的药物靶标之一。然而,目前对M〜(Pro)抑制的分子机制的理解受到缺乏可靠的结合亲和力等级和预测M〜(Pro)-inchibitor复合物的现有结构的限制。这项工作集成了数学(即代数拓扑)和深度学习(MATHDL),以提供137 SARS-COV-2M〜(PRO)抑制剂结构的结合亲和力的可靠等级。我们揭示了M〜(Pro)中的Gly143残留物是形成氢键的最具吸引力的部位,其次是Glu166,Cys145和His163。我们还鉴定了71个靶向的共价键合抑制剂。 Mathdl在PDBBind V2016核心集基准和仔细策划的SARS-COV-2抑制剂数据集上验证,以确保当前绑定亲和预测的可靠性。目前的结合亲和力排名,相互作用分析和片段分解为未来的药物发现努力提供了基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号